Publication date: Jul 11, 2019
July 10, 2019 – Partners HealthCare recently announced that its precision medicine biobank has enrolled over 100,000 individuals, helping researchers and clinicians at Brigham and Women’s Hospital, Massachusetts General Hospital, and other Partners institutions examine how a wide range of factors impact health and disease.
-In addition to the sample size, a key differentiator for our Biobank is the electronic portal that we developed to help researchers search for disease phenotypes and request the data samples that they need for their studies,” said Elizabeth Karlson, MD, Division of Rheumatology, Immunology, and Allergy at Brigham and Women’s Hospital, and one of the original leaders of the Biobank.
-The Biobank combines genotype data, electronic health record data with lifestyle information from a health survey so our researchers can easily search for and request the specifications that they are interested in looking at without the need to recruit the hundreds or thousands of patients often required to carry out a study. “
To date, the Biobank has provided samples or data to over 200 research studies, including current studies focused on genetic impact medications, the role of genetics in rheumatoid arthritis, and risk score associations between sleep duration and disease.
Greater participation in the Biobank enables us to increase the scale and scope of our research and provides our researchers with access to data and information that would otherwise take them years to source,” said Scott T. Weiss, MD, Principal Investigator at the Partners Biobank and Scientific Director of Partners HealthCare Personalized Medicine.
- Population-scale DNA test could make personalized medicine effective and affordable for all
- The immunobiology of MIF: function, genetics and prospects for precision medicine
- Information driven healthcare – Philip Anderson and Markus Lingman
- Moderated Discussion: Personalized genomics: a direct-to-patient approach